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Environmental enteropathy (EE) is a poorly defined state of intestinal inflammation without overt diarrhea that
occurs in individuals exposed over time to poor sanitation and hygiene. It is implicated as a cause of stunting and
malnutrition, oral vaccine failure and impaired development in children from low-income countries. The burden on
child health of malnutrition alone, which affects 25% of all children and is estimated to result in more than a million
deaths annually due to heightened susceptibility to infection, makes urgent a solution to EE. Efforts are thus underway
to treat EE even while work continues to identify it through the use of non-invasive biomarkers, and delineate its
pathogenesis. A recent study published in BMC Medicine reports the first randomized controlled phase I trial of an
anti-inflammatory drug for EE. The aminosalicylate mesalazine was found to be safe in short-term treatment of a small
number of severely malnourished children, although efficacy was not established. Whether such treatment trials are
premature, or instead a way both to understand and intervene in EE, is the focus of this article.
Please see related article: http://www.biomedcentral.com/1741-7015/12/133.
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Environmental enteropathy (EE) is an inflammatory con-
dition of the gut of residents of low-income countries
that is a result of exposure to poor sanitation and hygiene
[1-4]. The cause of EE is postulated to be inflammation
from continuous fecal-oral exposure to enteropathogens.
It is defined pathologically by decreased villous height and
lymphocytic infiltration in the small intestinal lamina pro-
pria and epithelium. It has been measured functionally by
abnormalities in sugar absorption using the lactulose:
mannitol test. Biomarkers of EE include intestinal inflam-
mation, gut barrier dysfunction and intestinal epithelial
health. Consequences of EE are hypothesized to include
linear growth faltering, impaired child development and
oral vaccine failure [1,2]. There is even the thought that
the current knowledge gap in the prevention and treat-
ment of malnutrition, where current interventions are
modeled to be less than one third effective, may be due to
EE (Table 1) [5].* Correspondence: wap3g@cms.mail.virginia.edu
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unless otherwise stated.Linear growth faltering occurs within the first two years
of life and then, for the most part, is irreversible, neces-
sitating early diagnosis if prevention or treatment is to be
successful (Figure 1) [6,7]. There is, therefore, emphasis
on identification of biomarkers that will detect EE when it
is still a subclinical illness. There are several candidate bio-
markers for which there is limited evidence of usefulness.
These include markers of gut inflammation such as fecal
neopterin and myeloperoxidase, of gut barrier dysfunction
including fecal alpha-1- antitrypsin, of intestinal mannitol
absorption, and intestinal epithelial regeneration measure
Reg1 (Table 2) [1,2,8,9]. It is a fair summary of the state of
current knowledge that EE is characterized by intestinal
injury and both gut and systemic inflammation.
Mesalazine as a treatment for environmental enteropathy
A study recently published in BMC Medicine by Jones
et al. [4] represents a first step in testing the role of
anti-inflammatory treatment for EE, in this case in the
setting of severe acute malnutrition. Therapy based on
suppression of inflammation is based on the hypothesis
that the inflammation of EE is deleterious, much as it is
in high-income countries for inflammatory bowel diseases,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 What works for the prevention and treatment of
malnutrition
Intervention Application
Improving women’s nutrition, especially before,
during and after pregnancy
Mother
Early and exclusive breastfeeding for first 6 months Mother-infant
Timely, safe, appropriate good quality
complementary feeding for 6-24 months
Infant
Micronutrient supplementation or fortification
(iron, zinc, vitamin A, iodine, folate, calcium, vitamin D)
Mother & infant
Promotion of responsive infant feeding practices Mother
Treatment of severe acute malnutrition Infant
Table 2 Biomarkers for studies of environmental
enteropathy
Biomarker Indicative of
Reg1 (fecal) Intestinal epithelial health
IGF-1 (plasma) Growth and proliferation
Calprotectin (fecal) Enteric inflammation
Myeloperoxidase (fecal) Enteric inflammation
Neopterin (fecal) Enteric inflammation
Alpha-1 anti-trypsin (fecal) Intestinal barrier disruption
Lipopolysaccharide (plasma) Intestinal barrier disruption
Lactulose:mannitol (urine) Intestinal barrier disruption





CRP, c-reactive protein; IGF, insulin-like growth factor; IL, interleukin.
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of course, is not necessarily the case, as the inflammation
may be protective against the enormous burden of enteric
infection suffered by these children [10].
The authors demonstrate the safety of oral mesalazine
in one- to five-year-old children undergoing treatment for
severe acute malnutrition in a slum in Nairobi, Kenya.
The study was conducted in the summer and fall of
2013. Forty-four children of average age 19 months,
who were undergoing treatment for severe acute mal-
nutrition (SAM) and who had evidence of EE, were ran-
domized to receive mesalazine or placebo. EE for the
purposes of the study was defined as a height-for-age
z-score ≤2 and systemic inflammation (as measured by an
erythrocyte sedimentation rate >20 mm/hour). Intestinal
inflammation was not a criterion for inclusion, although it
was present in 95% of the children, as evidenced by a fecal
calprotectin level higher than 100 μg/g. Enrollment cri-
teria included being between one and five years of age
and having uncomplicated SAM (defined by mid-upperFigure 1 Percentage of Bangladesh birth cohort infants
malnourished (WAZ ≤2) and stunted (HAZ ≤2) from birth to
12 months. Height-for-age Z (HAZ) and weight-for-age Z (WAZ)
scores determined using the World Health Organization’s Anthro
software, version 3.0.1 [3].arm circumference <11.5 cm or bilateral pedal edema).
Exclusion criteria included severe clinical illness, lack
of appetite and need for inpatient nutritional therapy.
The most common illnesses that resulted in exclusion
were hepatic dysfunction (elevation of liver enzymes was
seen in 8% of those screened), malaria and a need for in-
patient treatment.
All children received nutritional rehabilitation with
ready-to-use therapeutic food, deworming with meben-
dazole or albendazole, and a seven-day course of amoxi-
cillin. Therapy continued until cure, as measured by mid
upper arm circumference >11.5 cm and no edema at two
consecutive weekly visits. Mesalazine was administered at
30 mg/kg/day for days 1 to 7, and in the absence of identi-
fied toxicity, was escalated to 45 mg/kg/day for a further
21 days. The study was a double-blinded and randomized
placebo-controlled trial. Follow-up was for a total of 56
days. Primary outcomes were adverse events and compli-
ance with the intervention.
At completion of the 56-day follow-up period, nine-
teen children (34%) had not recovered, had died or had
not remained in follow-up. There were no significant
differences between the mesalazine and placebo groups
in any measure of toxicity or efficacy. There was a lower
erythrocyte sedimentation rate (ESR) and a trend towards
lower fecal calprotectin (P = 0.09) and immunoglobulin
G (IgG) Endocab antibodies (P = 0.07) at the end of 28
days of mesalazine treatment, but this was not sustained
at 56 days. There was no difference in other inflamma-
tory markers such as CRP, endotoxin, sCD14 platelets
or white cell count. There was also no difference in nu-
tritional outcome, although the rate of increase in mid-
upper arm circumference was higher in the placebo arm
of the study. In all children studied, systemic endotoxin
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growth, supporting a role of gut barrier dysfunction in
inflammation-induced stunting.
Perhaps the most important finding was that mesala-
zine was safe in this small study of malnutrition treat-
ment in infants. The safety of aminosalicylates, such as
mesalazine, is attractive in the setting of treatment of
already ill children who are suffering from SAM and
multiple enteric infections [10]. The doses used were
comparable to those used to induce remission for mild
to moderate Crohn’s disease. This is a potentially impor-
tant finding, as one could have anticipated a worsening
of symptoms if inflammation was, in fact, protective via
its action against enteropathogens in the gut (Figure 2).
However, this conclusion may be premature, as treatment
had no demonstrable effect on gut, and only a transient
effect on systemic, inflammation.
The lack of any demonstration of efficacy of mesa-
lazine could be for several reasons. First, a more pro-
longed treatment may be required, or at an earlier age
(the average age of the children treated was 19 months,
a time at which the majority of stunting has alreadyFigure 2 Frequency of enteropathogen detection in infants in Dhaka
collected at the time points indicated and assayed for 29 enteropathogens
summed for each sample; results are shown as mean ± SE. *Bonferroni adju
model used to identify differences in the number of pathogens detected b
study period). **Nonparametric Wilcoxon 2-sample tests were used to com
between diarrheal and surveillance samples for Virginia alone [10]. SE, standoccurred). However even in high-income countries these
agents are effective at inducing remission in less than
half of patients with ulcerative colitis and are not recom-
mended for inducing remission of Crohn’s disease [11].
Other treatment options for environmental enteropathy
There are other therapeutic options for EE that are being
considered. These include antibiotics, probiotics, other
anti-inflammatory agents, drugs targeted to tight junction
regulation, and epithelial healing. A study of the broad-
spectrum and relatively unabsorbed antibiotic rifaximin
was conducted in asymptomatic three- to five-year-old
children in rural Malawi [12]. The average HAZ of the
children was – 1.7 and 76% had an abnormally elevated
lactulose:mannitol ratio at the time of enrollment. Chil-
dren were randomized in a double-blinded, placebo-
controlled trial of 100 mg twice daily of rifaximin or
placebo for seven days. Twenty-eight days after the initi-
ation of treatment, the children were restudied with the
lactulose:mannitol test. No significant difference was ob-
served in the sugar absorption test. Treatment with rifaxi-
min was complicated by a significant increase in diarrheaversus Virginia. Diarrheal and nondiarrheal stool samples were
by molecular methods. The total number of enteropathogens was
sted P value <0.05 (determined with a linear mixed-effect regression
etween diarrheal and surveillance samples for each month during the
pare numbers of pathogens between Virginia and Dhaka samples and
ard error.
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this agent.
Budesonide is a synthetic corticosteroid that is pro-
duced in an enteric-coated formulation that results in
delivery of the drug to the ileum and ascending colon
where it has an anti-inflammatory effect. In clinical trials
budesonide has induced remission in up to a fifth of pa-
tients with ulcerative colitis [13]. Long-term use has un-
fortunately been complicated by decreased bone mineral
density, suggesting significant systemic uptake of the
drug leading to toxicity. α4β7 antagonists to prevent
migration of inflammatory lymphocytes to the gut are
another potential, but currently untested, therapeutic
approach [14].
Regulation of tight junction permeability by zonulin,
which is upregulated in celiac disease, is a potential the-
rapeutic target. Larazotide acetate is an octapeptide that
is a competitive inhibitor of the receptor binding domain
of zonulin and in early clinical trials has been shown to
decrease intestinal permeability following gluten chal-
lenge in celiac disease patients [14].
A different approach from anti-inflammatories is to
aid repair of the damaged gut with glutamine derivatives.
Glutamine is estimated to comprise a third of respiratory
metabolism in the gut and may be most readily adminis-
tered in dipeptide derivatives such as alanyl-glutamine
[15]. Glutamine supplementation was tested for its im-
pact on intestinal barrier function in Brazil in a study of
moderately and severely malnourished hospitalized chil-
dren (WAZ ≤2). The children were between 2 and 60
months of age. Fifty-three children were randomly as-
signed to receive in double-blind fashion standard for-
mula supplemented either with glutamine or as a control
glycine. The formula was administered for 10 days. The
outcome measure was a change in the lactulose/mannitol
test for intestinal barrier function. Supplementation with
glutamine significantly improved (that is, lowered) the lac-
tulose:mannitol ratio between day 1 and day 10 [15].
Likely at the heart of the problem of intestinal inflam-
mation and malnutrition is the gut microbiota. Current
probiotics are not of proven efficacy for any intestinal
condition and have not been tested for EE [16]. On the
horizon though is the potential for next generation pro-
biotics. A recent study examined the composition of
the microbiota in malnourished Bangladeshi children.
A microbiota maturity index was defined by measuring
the composition of the microbiota, based on 16S riboso-
mal RNA sequencing, in a cohort of children living in
an urban slum of Dhaka who had consistently healthy
growth. Children with severe acute malnutrition had
significantly immature microbiota, which was partially
restored by nutritional therapy. A total of 24 taxa of bac-
teria were identified that were most age-discriminatory
[17]. One can imagine in the near future that EE might beprevented or treated by restoration of key bacteria present
in the gut of healthy children.
Epigenetic contributions must also be considered. While
most stunting occurs after birth, there is a substantial con-
tribution of maternal nutritional status to the ultimate
outcome of the child, suggesting a role for epigenetics. In
fact, recently it has been shown that maternal methyl
donor pathway biomarkers are predictive of infant nut-
ritional status and are associated with DNA methylation
of metastable epialleles [18]. Interventions aimed at im-
proving the nutritional status of the mother are already
of known effectiveness, and could be acting in part via
epigenetics.
Finally, intestinal damage due to mycotoxins from
fungal contamination of food may also contribute to
stunting [19]. Aflatoxin, for example, causes intestinal
damage including increased leakiness of the gut bar-
rier, and aflatoxin-albumin adducts in plasma were as-
sociated with stunting in a dose-dependent manner in
one study. If validated at other sites, then this would
suggest an intervention aimed at protecting food pro-
duction from mycotoxin contamination.
The study by Jones et al. comes at a time when major
clinical studies of EE are nearing completion. These
include the Mal-ED study of malnutrition and enteric
diseases and the PROVIDE study of the impact of EE
on oral vaccine failure, both supported by the Bill &
Melinda Gates Foundation. These studies are defining
the measures of the enteropathy that results from gut
infection in infants, and estimating its impact on nu-
trition, vaccination and child development. These studies
have the promise of informing studies of treatment or pre-
vention of EE.
Conclusions
Anti-inflammatory agents are one proposed therapeutic
approach to EE. While it is increasingly clear that EE is
characterized, in part, by gut and systemic inflammation,
it is not clear if that inflammation is deleterious in the
way that it is for inflammatory bowel disease, or, con-
versely, protective against the near universal infections
of children with enteric pathogens. The study by Jones
and colleagues is encouraging for the lack of toxicity ob-
served with mesalazine, although tempered by the fact
that the anti-inflammatory effect of the drug was mo-
dest. There was a small decrement in the ESR but no
effect on the gut as measured by fecal calprotectin. It,
therefore, remains an open question of whether anti-
inflammatory therapy will be safe or effective but the fu-
ture is bright. A new understanding of EE is forthcoming
with the completion of multi-site observational studies
of infants in low-income countries, and a better under-
standing of pathogenesis is accompanying biomarker
discovery. As therapeutic trials begin for EE, the use of
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tion and repair promise to illuminate outcomes. Likely
only through rationally designed therapeutic trials with
emphasis on safety first, and with the use of biomarkers
to judge response, will we arrive at a treatment for this
most important of diseases.
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